Inhibikase Therapeutics, Inc. (IKT)
2.43
0.00 (0.00%)
USD |
NASDAQ |
Sep 09, 12:39
Inhibikase Therapeutics Shareholders Equity (Quarterly) : 153.33M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 153.33M |
| March 31, 2026 | 167.62M |
| December 31, 2025 | 172.90M |
| September 30, 2025 | 72.90M |
| June 30, 2025 | 80.05M |
| March 31, 2025 | 85.73M |
| December 31, 2024 | 94.87M |
| September 30, 2024 | -0.5306M |
| June 30, 2024 | 5.097M |
| March 31, 2024 | 6.777M |
| December 31, 2023 | 10.98M |
| September 30, 2023 | 15.02M |
| June 30, 2023 | 19.46M |
| March 31, 2023 | 25.32M |
| December 31, 2022 | 21.04M |
| September 30, 2022 | 25.14M |
| June 30, 2022 | 29.50M |
| March 31, 2022 | 34.01M |
| Date | Value |
|---|---|
| December 31, 2021 | 38.42M |
| September 30, 2021 | 43.16M |
| June 30, 2021 | 47.05M |
| March 31, 2021 | 8.037M |
| December 31, 2020 | 9.784M |
| September 30, 2020 | |
| June 30, 2020 | -4.831M |
| March 31, 2020 | -4.702M |
| December 31, 2019 | -4.49M |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | -0.778M |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | -1.399M |
| December 31, 2017 | -1.441M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 163.59M |
| Total Liabilities (Quarterly) | 10.26M |
| Current Ratio | 15.82 |
| Net Debt Paydown Yield | 0.01% |